Program

May 10 (Tue.)

Animal Prion Diseases Workshop

"Updated Diagnosis and Epidemiology of Animal Prion Diseases for Food Safety and Security"

(Sponsored by the OECD Co-operative Research Programme)

9:00-9:05 Opening Remarks

9:05-9:15 OECD programme

Rafael Blasco
INIA-Ministerio de Ciencia e Innovacion

9:15-10:50 Workshop 01-04

Chairs: Motohiro Horiuchi *(Hokkaido University)*
Corinne Lasmezas *(The Scripps Research Institute)*

WS-01 **Prion diseases in animals and zoonotic potential**
Juan Maria Torres
Centro de Investigacion en Sanidad Animal (CISA-INIA), Valdeolmos, Madrid, Spain

WS-02 **Scrapie in swine: A diagnostic challenge**
Justin J Greenlee
National Animal Disease Center, US Dept. of Agricultrue, Agricultural Research Service, United States

WS-03 **Epidemiology of Chronic wasting disease in Korea**
Hyun-Joo Sohn
Foreign Animal Disease Division (FADD), Animal and Plant Quarantine Agency (QIA), Korea

WS-04 **Ultra-sensitive detection of PrP^{Sc} of classical and atypical BSEs**
Yuichi Murayama
Influenza/Prion Disease Research Center, National Institute of Animal Health, Japan

10:50-12:45 Workshop 05-08

Chairs: Yoshifumi Iwamaru *(National Institute of Animal Health)*
Jean Manson *(The Roslin Institute, University of Edinburgh)*

WS-05 **RT-QuIC Assays in Humans and Animals**
Steven J Collins
The University of Melbourne, Australia

WS-06 **Pathology of TSEs**
John Spiropoulos
Animal and Plant Health Agency, Pathology Department, United Kingdom

WS-07 **Diagnosis of Atypical BSE and Isolation of the Agent**
Sandor Dudas
Canadian National and OIE BSE Reference Laboratory, Canadian Food Inspection Agency, National Center for Animal Disease, Lethbridge, Canada

WS-08 **Intra- and interspecies transmission of atypical BSE - What can we learn from it?**

Anne Balkema-Buschmann

Friedrich-Loeffler-Institut, Institute for Novel and Emerging Infectious Diseases, Germany

12:45-13:30 Luncheon Seminar 1 "Prion treatment by MC Water and other chemicals"

**Co-sponsored by Santa Mineral Co., Ltd.*

Chair: Koriki Jojima *(Former Minister of Finance)*

Speakers: Takashi Onodera *(Professor of University of Tokyo)*

Kouichi Furusaki *(General incorporated association Mineral Activation Technical Research Center)*

13:30-15:00 Workshop 09-11

Chairs: Hiroyuki Okada *(National Institute of Animal Health)*

John Spiropoulos *(Animal and Plant Health Agency)*

WS-09 **Pathogenesis and transmission of classical and atypical BSEs in cattle**

Cristina Casalone

Istituto Zooprofilattico Sperimentale del Piemonte, Liguria e Valle d'Aosta, Italy

WS-10 **Neuronal death and prion diseases**

Corinne Lasmezas

Department of Immunology and Microbial Science, Department of Neuroscience, The Scripps Research Institute, United States

WS-11 **Evaluating the species barriers of TSEs with transgenic mouse models**

Jean C Manson

The Roslin Institute, University of Edinburgh, United Kingdom

15:00-15:30 Closing Discussion

Chairs: Toshiro Kawashima *(Ministry of Agriculture, Forestry and Fisheries, Japan)*

Takashi Yokoyama *(National Institute of Animal Health, NARO)*

15:45-16:15 Opening Lecture

Chair: Motomasa Tanaka *(RIKEN Brain Science Institute, Lab for Protein Conformation Diseases)*

OL-01 **Implications of the folded in-register parallel beta-sheet structure of infectious prion amyloids**

Reed B. Wickner

National Institutes of Health; National Institutes of Diabetes and Digestive and Kidney Diseases; Laboratory of Biochemistry and Genetics, United States

16:15-16:45 Opening Lecture

Chair: Naomi Hachiya *(Tokyo Medical University)*

OL-02 **PrP^C function and prion toxicity**

Adriano Aguzzi

Institute of Neuropathology, University Hospital of Zürich, Schmelzbergstrasse, Zürich, Switzerland

May 11 (Wed.)

9:00-11:00 Invited Lectures "Conversion and Propagation"

Chairs: Noriyuki Nishida *(Molecular Microbiology and Immunology, Nagasaki University)*
Glenn Telling *(Colorado University)*

IL-01 **Molecular Determinants of Prions Infectivity**

Giuseppe Legname
Laboratory of Prion Biology, Department of Neuroscience, Scuola Internazionale Superiore di Studi Avanzati (SISSA), Trieste, Italy

IL-02 **Potential role of the environment on prion transmission: Plants, environmental surfaces and earthworms as carriers of infectious prions**

Claudio Soto
Mitchell Center for Alzheimer's Diseases and Related Brain Disorders, Department of Neurology, University of Texas Medical School at Houston, United States

IL-03 **How does recombinant prion protein become infectious? Progress in understanding the molecular basis of prion infectivity**

Jiyan Ma
Van Andel Institute, United States

IL-04 **Sorting of prion protein and PrP^{Sc} accumulation**

Keiji Uchiyama
Institute for Enzyme Research, Tokushima University, Japan

11:15-12:00 Oral Session

O-01 **Folding and misfolding pathways of prion protein**

Ryo P. Honda
Department of Molecular Pathobiochemistry, Gifu University Graduate School of Medicine, Japan

O-02 **HET-2s, an engineered, four-rung beta-solenoid protein as a model for the structure of PrPSc**

Holger Wille
Centre for Prions & Protein Folding Diseases, Canada

O-03 **Prion protein deficiency causes diverse proteome shifts in cell models that escape detection in brain tissue**

Mohadeseh Mehrabian
Tanz Centre for Research in Neurodegenerative Diseases; Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada

12:10-13:00 Luncheon Seminar 2 "From prion diseases to Alzheimer's disease"

**Co-sponsored by Daiichi Sankyo Co., Ltd.*

Chair: Hidehiro Mizusawa *(President / National Center of Neurology and Psychiatry)*
Speaker: Masahito Yamada *(Professor and Chairman / Department of Neurology & Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences)*

13:00-14:30 Invited Lectures "Pathogenesis I"

Chairs: Byron Caughey *(LPVD, Rocky Mountain Labs, NIAID, NIH)*
Shigeo Murayama *(Tokyo Metropolitan Institute of Gerontology)*

IL-05 **Prion structures, PIRIBS architectures, and real-time quaking-induced conversion (RT-QuIC)**

Byron Caughey
LPVD, Rocky Mountain Labs, NIAID, NIH, United States

IL-06 **Neuropathology of prion disease**

James W Ironside
National CJD Research & Surveillance Unit, University of Edinburgh, UK

IL-07 **Iatrogenic transmission of Creutzfeldt-Jakob disease**

Atsushi Kobayashi
Laboratory of Comparative Pathology, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan

14:45-16:15 Invited Lectures "Expansion of prion concept"

Chairs: Hidehiro Mizusawa *(NCNP)*
Joaquin Castilla *(Proteomic, CICbioGUNE, Spain)*

IL-08 **Revisiting supersaturation as a factor determining amyloid fibrillation**

Yuji Goto
Institute for Protein Research, Osaka University, Japan

IL-09 **Mechanisms of prion protein (mis) folding and aggregation explored by ultrafast kinetics**

Heinrich Roder
Fox Chase Cancer Center, United States

IL-10 **Tau / TDP-43 prions**

Masato Hasegawa
Department of Dementia and Higher Brain Function, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan

16:15-17:00 Oral Session

O-04 **Protein Folding Activity of the Ribosome: Key Player in Yeast Prion Propagation**

Cecile P Voisset
Inserm UMR 1078, University of Medecine of Brest, Etablissement Français du Sang (EFS) Bretagne, France; CHRU Brest, Morvan Hospital, Molecular Genetic Laboratory, Brest, France

O-05 **A local conformation of natively disordered yeast prion monomer determines interspecies prion transmissibility**

Toshinobu Shida
Department of Biological Information, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Yokohama, Japan; Laboratory for Protein Conformation Diseases, RIKEN Brain Science Institute, Wako, Japan

O-06 **Prion nucleation and propagation by amyloid beta in the yeast model**

Yury O. Chernoff
School of Biology, Georgia Institute of Technology, Atlanta, GA, USA; St. Petersburg State University, Russia

May 12 (Thu.)

9:00-10:30 Invited Lectures "Pathogenesis II"

Chairs: Shirou Mohri *(Department of Neurological Science, Tohoku University Graduate School of Medicine)*
Jean Manson *(Neurobiology, The Roslin Institute, University of Edinburgh)*

IL-11 Desigh of novel anti-prion compounds
Steven H. Olson
UCSF

IL-12 Activation state of glial cells in prion diseases
Motohiro Horiuchi
Laboratory of Veterinary Hygiene, Graduate School of Veterinary Medicine, Hokkaido University, Japan

IL-13 Transmission of prions to non human-primates: Implications for human populations
Jean-Philippe Deslys
CEA, Institute of Emerging Diseases and Innovative Therapies (iMETI), Division of Prions and Related Diseases (SEPIA), Fontenay-aux-Roses, France

10:45-12:00 Oral Session

O-07 Oral prion pathogenesis is reduced in the absence of CXCR5-expressing mononuclear phagocytes
Neil A. Mabbott
The Roslin Institute & R(D)SVS, University of Edinburgh, UK

O-08 Tau pathology in Creutzfeldt-Jakob disease: Novel insights
Gabor G. Kovacs
Medical University of Vienna, Institute of Neurology, Austria

O-09 Creutzfeldt-Jakob disease prion propagation in human iPS cells-derived astrocytes
Zuzana Krejciova
Institute for Neurodegenerative Diseases, University of California, San Francisco, United States; National CJD Research & Surveillance Unit, University of Edinburgh, United Kingdom

O-10 Role of Tunneling Nanotubes (TNTs) in intercellular spreading of prions and other protein
Chiara Zurzolo
Pasteur Institute, Department of Cell Biology and Infection, France

O-11 Structural role of the middle region in the prion protein in conformational conversion to the infectious form
Witold K Surewicz
Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, OH, USA

12:10-13:00 Luncheon Seminar 3 "Clinicopathological Feature of Genetic Prion Diseases in Japan"

**Co-sponsored by Novartis Pharma K.K.*

Chair: Yoshio Tsuboi *(Professor of Department of Neurology, Fukuoka University)*
Speaker: Nobuo Sanjo *(Associate Professor of Department of Neurology and Neurological Science, Tokyo Medical and Dental University)*

13:00-14:30 Invited Lectures "Human Prion Diseases: Diagnosis"

Chairs: Michael D. Geschwind *(Neurology, University of California, San Francisco)*
Ichirou Takumi *(Nippon Medical School)*

IL-14 **Variant CJD**
Robert G Will
National CJD Research and Surveillance Unit, United Kingdom

IL-15 **Genetic prion diseases**
Inga Zerr
National CJD Surveillance Center, Dept. of Neurology, Georg August University Göttingen, Germany

IL-16 **Biomarkers for prion disease**
Piero Parchi
Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, Italy; IRCCS, Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy

14:45-15:30 Oral Session

O-12 **PrPSc in the skin of CJD patients**
Wenquan Zou
Case Western Reserve University, United States

O-13 **Autopsy validation of second generation RT QuIC for diagnosis and differentiation of human prion diseases: Results from the US National Prion Disease Pathology Surveillance Center**
Jiri G. Safar
National Prion Disease Pathology Surveillance Center, Case Western Reserve University, United States

O-14 **Highly sensitive and specific detection of prions in blood of vCJD patients by PMCA**
Luis M Concha-Marambio
University of Texas Health Science Center, United States; Universidad de Los Andes, Facultad de Medicina, Chile

15:30-16:30 Invited Lectures "Animal Prion Diseases"

Chairs: Motohiro Horiuchi *(Graduate School of Veterinary Medicine, Hokkaido University)*
Candace Mathiason *(Microbiology, Immunology and Pathology, Colorado State University)*

IL-17 **Emergence of a novel bovine spongiform encephalopathy (BSE) prion from an atypical H-type BSE: An artificial laboratory strain or possible risk?**
Takashi Yokoyama
National Insitute of Animal Health, NARO, Japan

IL-18 **Rapid analysis of prion seeding activity in clinically accessible biological samples using magnetic particle extraction and realtime conversion**
Edward A Hoover
Microbiology, Immunology, Pathology, Colorado State University, United States

16:30-17:00 Oral Session

O-15 **Zoonotic Potential of CWD Prions: An Update**
Qingzhong Kong
Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA

O-16 **Puzzling out the BSE-human transmission barrier**
Natalia Fernandez-Borges
CISA-INIA, Valdeolmos, Madrid, Spain

May 13 (Fri.)

9:00-11:00 Invited Lectures-APPS 2016 "Human Prion Diseases: Surveillance"

Chairs: Steve John Collins *(Medicine, University of Melbourne, Australia)*
Yoshikazu Nakamura *(Department of Public Health, Jichi Medical University)*

IL-19 Epidemiological and clinical features of human prion diseases in Japan: Prospective 17-year surveillance

Masahito Yamada
Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences, Japan

IL-20 Chinese surveillance program for prion diseases

Xiao-Ping Dong
State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China

IL-21 Surveillance of prion diseases in Taiwan

Shun-Sheng Chen
Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, Taiwan

IL-22 Real-time quaking-induced conversion analysis for the diagnosis of sporadic Creutzfeldt-Jakob disease in Korea

Yong-Sun Kim
Ilsong Institute of Life Science, Hallym University, Department of Neurodegenerative Diseases, Korea CJD Diagnostic Center, Korea

11:15-12:05 Oral Session "APPS Cutting-edge young researcher"

O-17 Acceleration of Abeta brain amyloidosis by peripheral administration of disease associated aggregates

Rodrigo Morales
The University of Texas Health Science Center at Houston, United States

O-18 Amyloid beta pathology in iatrogenic Creutzfeldt-Jakob disease: A multi-center study

Ignazio Cali
Department of Pathology, Case Western Reserve University, School of Medicine, Cleveland, OH, USA

O-19 Prion acute synaptotoxicity at the CA1 region of the stratum radiatum

Simote T Foliaki
Department of Medicine, The University of Melbourne, Australia

O-20 Neuron and glial cell type-specific detection of PrPSc in prion-infected mouse brain by flow cytometry

Takeshi Yamasaki
Laboratory of Veterinary Hygiene, Graduate School of Veterinary Medicine, Hokkaido University, Japan

12:10-13:00 Luncheon Seminar 4 "α-Synuclein prions"

**Co-sponsored by GlaxoSmithKline K.K.*

Chair: TBD
Speaker: Masato Hasegawa *(Department Head, Department of Dementia and Higher Brain Function Tokyo Metropolitan Institute of Medical Science)*

13:00-15:00 Invited Lectures "Human Prion Diseases: Treatment"

Chairs: Neil Roy Cashman *(Medicine (Neurology), University of British Columbia)*
Yoshio Tsuboi *(Fukuoka University)*

IL-23 **Therapeutic approaches to prion infection and disease**

John Collinge
MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology and National Prion Clinic, National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom

IL-24 **Lessons from recent outcomes of clinical trials and therapeutic studies**

Katsumi Doh-ura
Department of Neurochemistry, Tohoku University Graduate School of Medicine, Japan

IL-25 **Prevention Trial in Fatal Familial Insomnia**

Fabrizio Tagliavini
IRCCS Foundation Carlo Besta Neurological Institute, Milan, Italy

IL-26 **Logical design of a therapeutic agent for prion diseases**

Kazuo Kuwata
United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Japan

15:15-16:00 Oral Session

O-21 **Towards prophylactic treatments for carriers of pathogenic PrP mutations**

Ruth Gabizon
Department of Neurology, Hadassah University Hospital, Israel; Granalix

O-22 **Eradication of PrPSc by poly-L-arginine in cells infected with prions**

Muhammad Waqas
Hanyang University, Korea

O-23 **Pre-implantation exclusion of embryos at risk for prion diseases**

Vardiella Meiner
Hadassah Hebrew University Hospital, Israel

Poster Session

May 11 (Wed.)-May 12 (Thu.) 17:15-19:15

P-001 **Employing Dynamic Mass Redistribution to Identify Pharmacological Chaperones for The Cellular Prion Protein**

Saioa R. Elezgarai
Department of Molecular Biochemistry and Pharmacology, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Spain; Dulbecco Telethon Institute, Centre for Integrative Biology (CIBIO), University of Trento, Trento, Italy

P-002 **Using small molecule reagents to help distinguish among prion structural models**

Christopher J. Silva
United States Department of Agriculture, ARS, WRRC, United States

P-003 **PrP, in conjunction with CD21/35, bolsters B lymphocyte antibody responses, yet infectious prions utilize this system for lymphoid replication**

Sarah J Kane
Colorado State University, United States

P-004 **Structural characterisation of ex vivo mammalian prions isolated from multiple strains**

Cassandra I.J Terry
MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology, United Kingdom

P-005 **Lack of stress protection by the cellular prion protein: An alternative role in regulating growth factor signalling**

Andrew R Castle
Roslin Institute, University of Edinburgh, Edinburgh, UK

P-006 **Structural and folding studies of the protective V127 variant of human prion protein**

Laszlo LP Hosszu
MRC Prion Unit, United Kingdom

P-007 **Non-equivalent binding sites for Abeta1-40 on PrP determine the oligomerisation pathway**

Katarina Grznarova
Brain and Spine Institute Paris, France; INRA/ National Institute of Agronomic Research, Molecular Virology and Immunology (VIM), Protein Macro-assembly and prion diseases (MAP2), Domaine de Vilvert, Jouy-en-Josas, France; CEA/French Alternative Energies and Atomic Energy Commission, Institute of Emerging Diseases, Innovative Therapies (SEPIA), Fontenay-aux-Roses, France

P-008 **Proteolytic shedding of PrP^{C}: Giving a little to gain a lot?**

Hermann C Altmeppen
Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

P-009 **Calibration of ultrasonic power and conformational analysis of MoPrP amyloid fibrils**

Kei-ichi Yamaguchi
United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Japan; Center for Emerging Infectious Diseases, Gifu University

P-010 **Polymorphism Analysis of Prion Protein Gene in Eleven Pakistani Goat Breeds**

Mohammad Farooque Hassan
China Agricultural University, Beijing, China; SBBUVAS, Sakrand Sindh Pakistan

P-011 **Matrix metalloprotease processing of the prion protein**

Victoria Lewis
Department of Medicine, RMH, The University of Melbourne, Australia

P-012 **A ZIP6-ZIP10 heteromer interacts with NCAM1, controlling its phosphorylation and integration into focal adhesion complexes during epithelial-to-mesenchymal transition**

Dylan Brethour
Tanz Centre for Research in Neurodegenerative Diseases; Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada

P-013 **Dimer-sized PrPSc formation detected by western blotting**

Kenta Teruya
Department of Neurochemistry Tohoku University Graduate School of Medicine, Japan

P-014 **The Prion Protein and genotoxic stress**

Malin R. Reiten
Norwegian University of Life Sciences, Norway

P-015 **Effects of cell growth suppression treatments on PrPSc accumulation in prion-infected cells; Paradoxical phenomena observed in butyric acid treatment**

Takako Hiyoshi
Department of Neurochemistry, Tohoku University Graduate School of Medicine, Japan

EP-001 **A novel system for massively parallel, quantitative analysis of PrP interactions and binding interfaces**

Stefanie M. Berges
University of Delaware, United States

EP-002 **The influence of Prnpb polymorphisms and the conserved 4-threonine stretch of Alpha-helix 2 on prion protein conversion**

Romany Abskharon
Van Andel Research Institute, United States; National Institute of Oceanography and Fisheries (NIOF), Cairo, Egypt

EP-003 **Solubilization of the aggregated-prion protein with the robust protein-unfolding activity of an oligomeric form of YDL178wp/ Unfoldin**

Naomi Hachiya
Tokyo Medical University, Pathophysiology, Japan

P-016 **Manipulation of Autophagic machinery Controls Exosomal Release of Prions and Lateral Prion Infection**

Basant A Abdulrahman
Department of Camparative Biology and Experimental Medicine, Canada

P-017 **Semisynthesis of lipidated prion protein variants**

Stefanie Hackl
Institute of Biological Chemistry, Department of Chemistry, University of Vienna, Waehringer Str.,Vienna, Austria

P-018 **In vitro seeding of amyloid plaques**

Kirsty A Ireland
The Roslin Institute, United Kingdom

P-019 **Discovery of anti-prion agents using a PyMOL plugin-based logical drug design platform NAGARA**

Biao Ma
United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan

P-020 ***Zinnia elegans* combined PrP^{BSE} complex increases the survival time of VM mice**

Hyo Jin Kim
Foreign Animal Disease Division, Animal and Plant Quarantine Agency, Korea

P-021 **Gene expression profiling analysis of *Rubus coreanus Miquel*-cured prion-infected MDBK cell line**

Hyo Jin Kim
Foreign Animal Disease Division, Animal and Plant Quarantine Agency, Korea

P-022 **The effects of PrPC glycosylation and cofactor molecules on species-specific prion strain susceptibility in the bank vole**

Cassandra M Burke
Department of Biochemistry, Geisei School of Medicine at Dartmouth, Hanover, New Hampshire, United States

P-023 **Autophagy is needed in opposing roles in the life cycle of prions and also impacts exosomal release of prions**

Hermann M Schatzl
University of Calgary, Comp. Biol. & Exp. Med., Canada

P-024 **Polymorphism of PrP amyloid-like fibrils can be defined by the concentration of seeds**

Vytautas Smirnovas
Vilnius University Institute of Biotechnology, Dept. Biothermodynamics and Drug Design, Lithuania

P-025 **Restricted propagation of sheep scrapie in hamsters**

Ronald A Shikiya
Creighton University, Medical Microbiology and Immunology, United States

P-026 **Comparison of the *in vitro* seeding activity of UK iatrogenic and sporadic Creutzfeldt-Jakob disease subtypes by real time quaking induced conversion**

Alexander H Peden
National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, University of Edinburgh, United Kingdom

P-027 **PrP glycosylation-independent amplification of prions using highly efficient cell-based protein misfolded cyclic amplification**

Mohammed Moudjou
INRA, UR892, Virologie Immunologie Moleculaires, Jouy-en-Josas, France

P-028 **Validating human stem cell derived neural cultures as a flexible model system in which to investigate neurodegenerative mechanisms**

James D Alibhai
The National CJD Research and Surveillance Unit, Centre for Clinical Brain Sciences, The University of Edinburgh, United Kingdom

P-029 **sCJD prion seeding activity in human urine by RT-QuIC**

Gabriele Piconi
National CJD Research and Surveillance Unit, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK

P-030 **Comparison of the in vitro amplification efficiency of UK iatrogenic and sporadic Creutzfeldt-Jakob disease subtypes by protein misfolding cyclic amplification**

Marcelo Barria Matus
National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, The University of Edinburgh, United Kingdom

P-031 **Determination of the amino terminal domains of the cellular prion protein that are required for highly efficient prion propagation**

Parineeta Arora
MRC, United Kingdom

P-032 **Prion-type dependent deposition of PRNP allelic products: Study in scrapie and BSE infected heterozygous ARR/VRQ sheep**

Jan PM Langeveld
Central Veterinary Institute part of WageningenUR, Netherlands

P-033 **PrP quaternary structure and prion capacity to cross the species barrier**

Angelique Igel
INRA UR892 VIM, France

P-034 **Influence of a polymorphism in the highly conserved hydrophobic core region on chronic wasting disease prion propagation and pathogenesis**

Samia Hannaoui
University of Calgary, Faculty of Veterinary-Medicine, Dept. of Ecosystem and Public Health, Canada

P-035 **From misfolding to aggregation: Sequence effects on conformational properties of amyloidogenic peptides implicated in neurodegeneration**

Nikolay Blinov
National Institute for Nanotechnology, Canada; Department of Mechanical Engineering, University of Alberta, Alberta, Canada

P-036 **Modulation of protein quality control pathways as a novel intervention strategy in prion diseases**

Simrika Thapa
Department of Comparative Biology and Experimental Medicine, Faculty of Veterinary Medicine, University of Calgary, Canada

P-037 **Effect of substitutions equivalent to bank vole 109I polymorphism in the spontaneous misfolding ability of PrPs from several mammalian species**

Hasier Erana
CIC bioGUNE, Parque Tecnologico de Bizkaia, Derio, Spain

P-038 **Differences in the denatured state of wild-type and E211K bovine PrP**

Eric M Nicholson
USDA / Agricultural Research Service / National Animal Disease Center, United States

P-040 **Cellular phenotypes of prion disease in skin-derived fibroblasts of asymptomatic PrP mutation carriers and sporadic CJD patients**

Wenquan Zou
Case Western Reserve University, Pathology, United States

P-041 **Gerstmann-Sträussler-Scheinker diseases with P102L, A117V and F198S mutations transmit efficiently and produce distinct pathological phenotypes in bank voles**

Laura Pirisinu
Istituto Superiore di Sanità, Dept. of Veterinary Public Health and Food Safety, Italy

P-042 **Identification of the origin of Creutzfeldt-Jakob disease after cadaver-sourced pituitary growth hormone treatment using an amplification property in protein misfolding cyclic amplification**

Atsuko Takeuchi
Department of Neurological Science, Tohoku University Graduate School of Medicine, Japan

P-043 **Curing PrP-sc by a gene-interference strategy targeting biosynthesis of undersulfated heparan sulphate**

David Cullis-Hill
Sylvan Scientific Pty Ltd., Australia

P-044 **Kinetics of RML prion propagation in three inbred mouse strains with indistinguishable expression levels of PrP^C but distinct incubation periods**

Malin K Sandberg
MRC Prion Unit, Department of Neurodegenerative Disease, United Kingdom

P-045 **A cellular bioluminescence assay detects prion protein dimerization and aggregation upon infection**

Gültekin Tamgüney
German Center for Neurodegenerative Diseases (DZNE), Germany

P-046 **Altered dynamics of membrane microdomain distribution in chronically prion-infected cells**

Peter C. Kloehn
UCL Institute of Neurology, MRC Prion Unit, United Kingdom

P-047 **A Comprehensive Study of The Potential Resistance of The Canidae Family to Prion Infection**

Natalia Fernandez-Borges
CISA-INIA, Carretera de Algete a El Casar s/n, Valdeolmos, Madrid, Spain; CIC bioGUNE, Derio, Bizkaia, Spain

P-048 **Classification of anti-prion compounds based on the binding properties to prion proteins**

Yuji O. Kamatari
Life Science Research Center, Gifu University, Japan

P-049 **A platinum compound targeting the cysteine residues of disease-related form of prion protein in cell lysates**

Yuji Sakasegawa
Department of Neurochemistry, Tohoku University Graduate School of Medicine, Japan

EP-004 **Single Molecule Studies of Protein Aggregates in Prion Diseases**

Chieh Sang
Department of Chemistry, University of Cambridge, United Kingdom

EP-005 **Real-time quaking-induced conversion analysis for the diagnosis of sporadic Creutzfeldt-Jakob disease in Korea**

Jeong Ho Park
Ilsong Institute of Life Science, Hallym University, Korea; Korea CJD Diagnostic Center, Hallym University

EP-006 **Diffusion-weighted images in patients with dura mater graft-associated Creutzfeldt-Jakob disease**

Kenji Sakai
Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science, Japan

EP-007 **Post-translational modifications in the prion protein determine disease outcome**

Christina Sigurdson
Pathology, University of California, United States

EP-008 **A self-propagating protease-resistant baculovirus-derived recombinant prion protein is spontaneously generated by protein misfolding cyclic amplification at high temperature**

Morikazu Imamura
National Institute of Animal Health, Japan

EP-009 **Emergence and Host Dependent Propagation of Chronic Wasting Disease strains**

Camilo Duque
Center for Prions and Protein Folding Diseases, Canada

P-050 **A kinetic model of the aggregation of alpha-synuclein provides insights into prion-like spreading**

Marija Iljina
Chemistry Department, University of Cambridge, United Kingdom

P-051 **Proteomic screening and identification of a structural protein of [NSI+] prion determinant in yeast Saccharomyces cerevisiae**

Anton A. Nizhnikov
Dept. of Genetics and Biotechnology, St. Petersburg State University; St. Petersburg Branch, Vavilov Institute of General Genetics, Russian Academy of Sciences, Universitetskaya nab, St. Petersburg, Russia

P-052 **Aggregation of QN-rich fragment of Gln3 in yeast Saccharomyces cerevisiae is modulated by [PSI+] and [PIN+] prions**

Kirill S. Antonets
Dept. of Genetics and Biotechnology, St. Petersburg State University, Russian Federation; St. Petersburg Branch, Vavilov Institute of General Genetics, Russian Academy of Sciences

P-053 **Prion-like Proteins and Disease Propagation in ALS**

Neil R Cashman
Neurology, University of British Columbia, Canada

P-055 **Yeast-based Search for New Human Amyloidogenic Proteins**

Nina V. Romanova
St Petersburg State University, St Petersburg, Russia

P-056 **Analysis of Interspecies Prion Transmission in Yeast**

Aleksandr A. Rubel
St Petersburg State University, St Petersburg, Russia

P-057 **Formation of a metastable stress-inducible prion by the yeast short-lived actin associated protein**

Tatiana A. Chernova
Department of Biochemistry, Emory University School of Medicine, Atlanta, USA

P-058 **Emergence and evolution of prion and prion-like proteins in the eukaryotic domain**

Paul M Harrison
McGill University, Dept. of Biology, Canada

P-059 **Latent structural variation in a yeast prion monomer determines strain phenotypes**

Motomasa Tanaka
RIKEN Brain Science Institute, Japan

P-060 **Chaperone sorting factor Cur1 exhibits differential effects on yeast prions**

Galina A. Zhouravleva
Dept. of Genetics and Biotechnology, St Petersburg State University, Russian Federation; Laboratory of Amyloid Biology, St Petersburg State University

P-061 **Modulation of Yeast Prion Strain Competition by Host Genetic Background and Molecular Chaperons**

Chang-I Yu
Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan, R.O.C.; Department of Life Sciences and Institute of Genomic Sciences, National Yang-Ming University, Taipei, Taiwan, R.O.C.

P-062 **Prophylactic efficacy of orally administered compounds on the progression of scrapie induced motor coordination deficits**

Damani N Bryant
Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, United States

P-063 **We shall overcome prion diseases only by using both scientific and empiric findings or why honoring discovery and development of avermectins with 2015 Nobel Prize for physiology or medicine does not decrease their chronic toxicity especially neural degeneration increasing the susceptibility for prion diseases**

Andreas Becker
Independent Institute for Holistic Prion Research, Germany

P-064 **Low activity of complement in the cerebrospinal fluids of the patients with various prion diseases**

Cao Chen
State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, China; Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University

P-065 **Myelin basic protein citrullination as predictive marker of demyelination contributes to the pathogenesis of prion diseases**

Byungki Jang
Ilsong Institute of Life Science, Hallym University, Anyang, Korea

P-066 **Emergence of two prion subtypes in ovine PrP transgenic mice infected with human MM2-cortical Creutzfeldt-Jakob disease prions**

Vincent Beringue
INRA, France

P-067 **The density of M cells in the epithelium overlying the Peyer's patches influences susceptibility to oral prion disease**

Neil A. Mabbott
The Roslin Institute & R(D)SVS, University of Edinburgh, UK

P-068 **Challenging the central hypothesis that misfolded prion protein accumulation, spread and distribution predicts regions of neurodegeneration**

James D Alibhai
The Roslin Institute, The University of Edinburgh, United Kingdom

P-069 **Transcriptome analysis of microglia and astrocytes in prion-infected mice**

Minori Kuroda
Laboratory of Veterinary Hygiene, Graduate School of Veterinary Medicine, Hokkaido University, Japan

P-070 **Transmission properties of human PrP 102L prions challenge the relevance of mouse models of GSS**

Emmanuel A Asante
MRC Prion Unit and Department of Neurodegenerative Disease, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom

P-071 **Impairment of protease activated receptors calcium signaling in prion infected cell lines**

Tibor Mosko
Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University in Prague, Czech Rep.

P-072 **Defining the Microglia Response during the Time Course of Chronic Neurodegeneration**

Jean C Manson
University of Edinburgh, United Kingdom

P-073 **The route of inoculation of kuru during traditional mortuary feasts in the kuru-affected region**

Jerome T Whitfield
MRC Prion Unit, United Kingdom

P-074 **New insights in the transfusional risk assessment of variant Creutzfeldt-Jakob Disease: Transfusional transmission of vCJD prions in the absence of detectable abnormal prion protein**

Emmanuel E Comoy
CEA DRF/iMETI/SEPIA, Fontenay-aux-Roses, France

P-075 **Neuronal toxicity of the expression of human PrP with the E200K mutation in the mecanosensitive neuronal system of the nematode C. elegans**

Bizat M. Nicolas
INSERM; INSERM UMRS 1127, CNRS UMR 7225, UPMC, Institut du Cerveau et de la Moelle Epiniere, G.H. Pitie-Salpetriere, Paris, France; Université Paris Rene Descartes, Paris, France

P-076 **Impact of human prion proteins with E211D or E211Q mutation on tau alterations in cultured cortical neurons**

Alexianne Gougerot
Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMRS 975, Equipe Maladie d'Alzheimer - Maladies à Prions, Paris, France; Centre National de Reference des Agents Transmissibles Non Conventionnels (InVS), France

P-077 **Is sporadic CJD an acquired disease? A review of the UK CJD cases**

Patrick JM Urwin
National CJD Research & Surveillance Unit, United Kingdom

P-078 **Subcutaneous Administration of Mouse Recombinant Prion Protein Resistant or RML Trigger Long-term Alterations in Composition of Intestinal Microbiota in FVB/N Female Mice**

Burim Ametaj
University of Alberta, Dept. of Agricultural, Food and Nutritional Science, Canada

P-079 **Effect of scrapie infection on expression of endogenous retroviral genes in sheep lymphoid tissues**

Fiona Houston
The Roslin Institute, United Kingdom

P-080 **Early Age Oral Administration of Mouse Recombinant Prion Protein Resistant or RML Trigger Lifelong Modifications in the Composition of Intestinal Microbiota in FVB/N Female Mice**

Suzanna M Dunn
University of Alberta, Department of Agricultural, Food and Nutritional Science, Canada

P-081 **Importance of Complement Receptor CD21 in Establishing Peripheral Prion Accumulation**

Eric M Swanson
Colorado State University, United States

P-082 **Infectious CWD prions detected at the feto: Maternal interface of experimental and free-range naturally-exposed cervids**

Candace K Mathiason
Microbiology, Immunology and Pathology, United States

P-083 **Prion strain-dependent effect of macroautophagy on abnormal prion protein degradation**

Daisuke Ishibashi
Department of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences, Japan

P-084 **Differential effects of anti-prion treatments highlight differences in the pathogenesis of sporadic and familial forms of prion disease and identifies novel mode of action for pentosan polysulfate**

Victoria A Lawson
Department of Pathology, The University of Melbourne, Australia

P-085 **Withdrawn**

P-086 **Neuropathological analysis of hyperintense signals on magnetic resonance imaging in MM1+2 type sporadic Creutzfeldt-Jakob disease**

Ayano Shima
Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences, Japan

P-087 **HDAC6 alleviates prion peptide-mediated neuronal death via modulating PI3K-Akt-mTOR pathway**

Lifeng Yang
National Animal Transmissible Spongiform Encephalopathy Laboratory, China Agricultural University, Beijing, China

P-088 **Transmission of experimental CH1641-like scrapie to bovine PrP overexpression mice**

Kohtaro Miyazawa
Influenza and Prion Disease Research Center, National Institute of Animal Health, NARO, Japan

EP-014 **Progranulin: Potential regulator in pathogenesis of Prion disease?**

Hee-Young Lim
Hallym University, Ilsong Institute of Life Science, Korea

EP-015 **Pathognomonic inter-tissue transcriptome analysis following prion spread by intraperitoneal infection**

Yeong-Gon Choi
Ilsong Institute of Life Science, Hallym University, Korea

EP-016 **Characterization of newly established neuronal cell lines from Bank Vole prion protein transgenic mice**

Hong-Seok Choi
Ilsong Institute of Life Science, Hallym University, Korea

EP-017 **Comparison of abnormal isoform of prion protein in prion-infected cell lines and primary cultured neurons by PrP^{Sc}-specific immunostaining**

Misaki Tanaka
Laboratory of Veterinary Hygiene, Graduate School of Veterinary Medicine, Hokkaido University, Japan

EP-018 **RNA editing: A novel approach to understand CJD pathogenesis**

Eirini Kanata
Prion Diseases Research Group, School of Health Sciences, Department of Pharmacy, Aristotle University of Thessaloniki, Greece

EP-019 **Interspecies transmission of atypical L-BSE prion to non-human primates (cynomolgus macaques) alleviates PrPSc glycoform profile of cattle L-BSE trait, but preserves incompetent transmissibility to inbred mice**

Ken'ichi Hagiwara
Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Japan

P-089 **New CSF-based approaches in the differential diagnostic of sCJD**

Franc Llorens
German Center for Neurodegenerative Diseases, Germany; Department of Neurology, Clinical Dementia Center, University Medical Center Gottingen, Germany

P-090 **Identification of microRNA signature in sCJD reveals massive regional and subtype-dependent regulation**

Thüne Katrin
Department of Neurology, Medical University Göttingen, Germany; German Center for Neurodegenerative Diseases (DZNE)

P-091 **Variant CJD: Lessons in Public Health**

Abigail B Diack
The Roslin Institute, University of Edinburgh, United Kingdom

P-092 **Identification of new molecular alterations in Fatal Familial Insomnia**

Isidro Ferrer
University of Barcelona; Institute of Neuropathology, Bellvitge University Hospital, Hospitalet de Llobregat, Spain; CIBERNED, Institute Carlos III, Spain

P-093 **An autopsy case of MM1-type sporadic Creutzfeldt-Jakob disease with 1-month total disease duration presenting with early disease pathology**

Yasushi Iwasaki
Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Japan

P-094 **Familial Creutzfeldt-Jacob disease (V180I) as the initial presenting depression: Case report**

Dooeung Kim
Neurology, Veterans Hospital, Seoul Medical Center, Korea

P-095 **A survey of anti-prion compounds using the real time-quaking induced conversion (RT-QuIC)**

Jae Wook Hyeon
National Institute of Health (Korea CDC), Korea

P-096 **Proteomics Analyses for the Global Proteins in the Brain Tissues of Different Human Prion Diseases**

Qi Shi
Prion Department, National Institute for Viral Disease Control and Prevention, China CDC, China

P-097 **Genetic Creutzfeldt-Jacob disease with V180I mutation in Korea**

Jae W Kim
Dong-A University, Korea

P-098 **Genome differences between genetic Creutzfeldt-Jakob Disease's patients with V180I mutation and healthy individuals and associations with other neurodegenerative disorders**

Sol Moe Lee
Division of Zoonoses, Center for Immunology & Pathology, National Institute of Health, Korea Centers for Disease Control & Prevention, Korea

P-099 **A Therapeutic Approach for Creutzfeldt-Jakob Disease by DNAzyme-mediated Knockdown of the Prion Protein**

Julian Victor
Institut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf, Germany

P-100 **Differential association of amyloid-β with PrP^{Sc} pathology in each genetic prion disease**

Fumiko Furukawa
Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Tokyo, Japan

P-101 **Withdrawn**

P-102 **Brain Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) and Neuropathologic Correlations in Human Prion Diseases**

Brian S Appleby
Case Western Reserve University, National Prion Disease Pathology Surveillance Center, United States

P-103 **Celia´s encephalopathy: A new member of the group of protein misfolding-mediated neurodegenerative diseases**

Jesús R. Requena
University of Santiago de Compostela, Spain

P-104 **AR-12 and its derivatives, a potential new therapeutic agent against prions**

Hermann M Schatzl
University of Calgary, Comp. Biol. & Exp. Med., Canada

P-105 **An autopsy-verified case of FTLD-TDP with upper motor neuron predominant motor neuron disease mimicking MM2-thalamic-type sporadic Creutzfeldt-Jakob disease**

Yuichi Hayashi
Department of Neurology and Geriatrics, Gifu University Graduate School of Medicine, Japan

P-106 **Temporal resolution of PrP^{Sc} transport, PrP^{Sc} accumulation, activation of glia and neuronal death in retinas from C57Bl/6 mice inoculated with RML scrapie: Relevance to biomarkers of prion disease progression**

M. Heather West Greenlee
Biomedical Sciences, Iowa State University College of Veterinary Medicine, United States

P-107 **CSF analysis of patients with human prion disease**

Katsuya Satoh
Department of Locomotive Rehabilitation Science, Unit of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan

P-108 **Prospective surveillance data of human prion disease in the Chugoku and Shikoku regions of Japan**

Kota Sato
Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan

P-109 **Tau / p-Tau and the altered regulatory response of Rab7a contributing the fast progression rate in Creutzfeldt-Jakob disease (CJD) and rapid progressive Alzheimer's disease (rpAD)**

Saima Zafar
Department of Neurology, Clinical Dementia Center and DZNE, Georg-August University, University Medical Center Goettingen (UMG), Germany

P-110 **Detection of disease-specific PrP and infectivity in the blood of mice with preclinical prion disease - implications and applications for public health**

Elizabeth B Sawyer
MRC Prion Unit, United Kingdom

P-111 **Iatrogenic Creutzfeldt-Jakob disease in human growth hormone recipients in the United Kingdom**

Mark W Head
National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, University of Edinburgh, United Kingdom

P-112 **Assessing the disease-modifying role of TREM2 in a prion model of neurodegeneration**

Jean C Manson
The Roslin Institute, United Kingdom

P-113 **Two International Ring-trials demonstrate that CSF RT-QuIC is a robust and reliable test for diagnosing sporadic CJD**

Neil I. McKenzie
University of Edinburgh, National CJD Research and Surveillance Unit, Western General Hospital, Edinburgh, United Kingdom

P-114 **Enhanced Creutzfeldt-Jakob disease surveillance in the older population in the UK: Biochemical analysis for PrP^{Sc}**

Helen M Yull
National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, University of Edinburgh, UK

P-115 **Accuracy of Creutzfeldt-Jakob disease diagnosis using RT-QuIC testing of nasal and cerebrospinal fluid samples**

Gianluigi Zanusso
University of Verona, Department of Neurosciences, Biomedical and Motor Sciences, Italy

P-116 **A novel approach combining 3D human cell culture and 3D microscopy to assess prion infectivity**

Ferid Nassor
CEA DRF/iMETI/SEPIA, Fontenay-aux-Roses, France

P-117 **Iatrogenic CJD after human GH treatment in France: Effect of sex, dose and genetics on the susceptibility of a possible infection by a V2 sCJD strain**

Laurene Peckeu
Team Alzheimer's and Prion Diseases, Inserm UMR-1127/CNRS UMR 7225, Université Pierre & Marie Curie - Paris 6, France

P-118 **Volumetric analysis and Diffusion Tensor Imaging in Creutzfeldt-Jakob disease and fatal insomnia point to the thalamus as a key structure in disease pathogenesis**

Oriol Grau-Rivera
Neurological Tissue Bank of the Biobanc-Hospital Clinic-IDIBAPS, Spain

P-119 **Prion protein interactome: Identifying novel targets in rapidly progressive Alzheimer's disease**

Mohsin Shafiq
Clinical Dementia Center, Department of Neurology and Psychiatry, University Medical Center Goettingen, Germany

P-120 **Assessment of doxycycline treatment on prion deposition in the olfactory epithelium of patients with Fatal Familial Insomnia: Possible mirroring of the CNS alterations**

Fabio Moda
IRCCS Foundation Carlo Besta Neurological Institute, Department of Neuropathology and Neurology, Italy

P-121 **Unusually young prion disease cases in the United States, 1979-2014**

Ryan A. Maddox
National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention (CDC), USA

P-122 **End-Point Quaking-Induced Conversion (EP-QuIC) as a Routine Test for sCJD in Canada**

J. David Knox
Public Health Agency of Canada, Canada; Department of Medical Microbiology, University of Manitoba

P-123 **Rapid testing for Creutzfeldt-Jakob disease in donors of human tissues**

David M. Asher
US Food and Drug Administration, Center for Biologics Evaluation and Research, United States

P-124 **Rational design and optimization of drug leads targeting prion-like misfolding and aggregation of SOD1 enzyme in Amyotrophic Lateral Sclerosis**

Vijaya Kumar Hinge
National Institute for Nanotechnology, Canada; Department of Mechanical Engineering, University of Alberta, Alberta, Canada

P-125 **Novel detection technique of early Alzheimer's disease from blood using fluorescence spectral microscopy**

Shigeki Tsutsui
Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Canada

P-126 **Geographic risk of variant Creutzfeldt-Jakob disease: A risk ranking model to evaluate options for blood donor deferral policies in the US**

Hong Yang
US Food and Drug Administration, United States

P-127 **Early response of Cofilin1 pathway in Creutzfeldt Jakob disease**

Neelam Younas
Department of Neurology, Clinical Dementia Center and DZNE, Georg-August University, University Medical Center Goettingen (UMG), Germany

P-128 **Clinical courses of patients with Creutfeldt-Jakob disease in Shizuoka Institute of Epilepsy and Neurological Disorders, Japan**

Tomokazu Obi
Shizuoka Institute of Epilepsy and Neurological Disorders, Department of Neurology, Japan

P-129 **Epidemiologic features of human prion diseases in Japan: A prospective 15-year surveillance study**

Ryusuke Ae
Division of Public Health, Center for Community Medicine, Jichi Medical University, Japan

P-130 **Diagnostic significance of Periodic synchronous discharges in Japanese surveillance of Creutzfeldt-Jakob disease**

Yoshiyuki Kuroiwa
Teikyo University Mizonokuchi Hospital, Japan

P-131 **Creutzfeldt-Jakob disease associated with a V203I homozygous mutation in the prion protein gene**

Junji Komatsu
Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences, Japan

P-132 **Clinical features in the patients with V180I, M232R and P102L of PRNP**

Erika Abe
Neurology, National Hospital Organization Akita Hospital, Japan

P-133 **Suspected prion disease cases referred to the National Prion Disease Pathology Surveillance Center, United States**

Ermias D Belay
Centers for Disease Control and Prevention, Atlanta, Georgia, United States

P-134 **CSF biomarkers, Tau and 14-3-3, in genetic and sporadic Creutzfeldt-Jakob disease patients in Israel**

Zeev Meiner
Physical Medicine and Rehabilitation, Hadassah-Hebrew University Hospital, Israel

P-135 **The Japanese Consortium of Prion Disease (JACOP) for patients' registration and clinical studies of Prion diseases in Japan**

Yuko Ishimura
National Center Hospital, National Center of Neurology and Psychiatry, Japan

P-136 **Cerebral beta-amyloidosis in patients with dura mater graft-associated Creutzfeldt-Jakob disease**

Tsuyoshi Hamaguchi
Department of Neurology, Kanazawa University Hospital, Japan

P-137 **Withdrawn**

P-138 **Clinically and neuropathologically atypical autopsied case of sporadic Creutzfeldt-Jakob disease MM type1**

Yuta Nakano
Department of Neuropathology, Tokyo Metropolitan Geriatric Hospital and Institution of Gerontology, Japan

P-170 **CJD International Support Alliance (CJDISA) - The voice, the face, the human story behind this horrific disease**

Suzanne Solvyns
CJD International Support Alliance, Australia; CJD Support Group Network Australia; CJD Insight; CJD Foundation USA; CJD Support Network Japan; CJD Support Network UK; A.I.En.P. Italy; MCJ-HCC France; CJK Initiative e.V. Germany; CJD Foundation Israel

P-139 **How can we increase the number of prion autopsy in Japan?**

Masaki Takao
Saitama International Medical Center; Mihara Memorial Hospital, Japan

P-140 **Wire-QuIC: A new detection system of human prion**

Tsuyoshi Mori
Department of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences, Japan

P-141 **The first Italian case of Creutzfeldt-Jakob disease with V180I mutation in the PrP gene (PRNP)**

Maurizio Pocchiari
Istituto Superiore di Sanità, Cell Biology and Neurosciences, Italy

P-142 **Evaluation of CSF RT-QuIC diagnostic assay for Creutzfeldt-Jakob and other human prion diseases: The Italian Surveillance Unit experience**

Maurizio Pocchiari
Istituto Superiore di Sanità, Cell Biology and Neurosciences, Italy

P-143 **A case of slowly progressive familial prion disease with a five-octapeptide repeat insertion**

Makoto Takahashi
Department of Neurology, Kanto Central Hospital, Japan

P-144 **Human Prion Diseases Surveillance and Registration System in Japan**

Tadashi Tsukamoto
Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Japan

P-171 **Presymptomatic genetic testing for genetic prion disease: What should we consider and how should we deal with it?**

Chieko Tamura
FMC Tokyo Clinic, Japan; Genetic Counseling Clinic, Juntendo University Hospital

EP-022 **Agraphia of Kanji (Chinese characters): An early symptom of sporadic Creutzfeldt-Jakob disease in a Japanese patient**

Keiko Nakamura
Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences, Japan

EP-023 **Establishment of high-sensitivity detection method of FABP3 in cerebrospinal fluid of CJD patients**

Yumi Tanaka
Department of Molecular and Applied Biosciences, Hiroshima University Graduate School of Biosphere Science, Japan

EP-024 **Annual incidence of Gerstmann-Stäussler-Scheinker disease in Kyushu region of Japan**

Yoshio Tsuboi
Department of Neurology, Fukuoka University, Japan

EP-025 **Generation of Alzheimer's disease (AD) genetic patients reprogrammed stem cells (iPS) as tools for the study of AD physiopathology**

Laura Auboyer
Institute for Regenerative Medicine and Biotherapy (IRMB), France

EP-026 **SPECT study of the Nigrostriatal Dopaminergic System in Creutzfeldt-Jakob disease: A case report and literature review**

Tzu-Hsuan Chen
Department of Physical Medicine and Rehabilitation,Shin Kong Wu Ho-Su Hospital, Taipei, Taiwan

EP-027 **Epidemiological survey of Gerstmann-Straussler-Scheinker disease with codon 102 mutation in Japan**

Hiroyuki Murai
Department of Neurological Therapeutics, Kyushu University, Japan

EP-028 **A case of subacute progressive dementia presenting with M129V mutation of the prion protein gene and positive RT-QUIC assays**

Rie Motoyama
Neurology, Tokyo Metropolitan Geriatric Hospital, Japan

EP-029 **Inhibition of The interaction between Prion Protein and Amyloid beta protein by Computational Methods; A strategy Against Alzheimer's Disease**

Michael K Fonjang
German School for Simulation Science (GRS), Cameroon

P-145 **Estimating chronic wasting disease resistance in cervids using real time quaking-induced conversion**

Nicholas J Haley
Department of Microbiology and Immunology, Midwestern University, United States

P-146 **RT-QUIC detection in CWD infected cervid and TgElk mice tissues**

Hyun Joo Sohn
Animal and Plant Quarantine Agency (QIA), Korea

P-147 **Infection and detection of PrPCWD in soil from CWD infected farm in Korea**

Hyun Joo Sohn
Animal and Plant Quarantine Agency (QIA), Korea

P-148 **Prion treatment by electrolyzed alkaline water and other chemicals**

Takashi Onodera
University of Tokyo, Japan

P-149 **Key Features of the Australian BSE Food Safety Assessment Process**

Hong Jin
Food Standards Australia New Zealand, Australia

P-150 **Study of the allelic variants at codon 222 in the genome goat for the detection of susceptibility to SCRAPIE, through the mass spectrometry (MALDI-TOF)**

Daniele Macri'
Istituto Zooprofilattico Sperimentale della Sicilia, Italy

P-151 **Phenotypic plasticity of chronic wasting disease prions**

Christina M Carlson
U.S. Geological Survey National Wildlife Health Center, United States

P-152 **Sensitive and Rapid Diagnosis of Goat Prion Diseases by Real Time Quaking Induced Conversion Assay**

Alessandra Favole
Istituto Zooprofilattico Sperimentale del Piemonte Liguria e Valle d'Aosta, Italy

P-153 **Experimental oral transmission of chronic wasting disease to sika deer (*Cervus nippon*)**

Gordon Mitchell
National & OIE Reference Laboratory for Scrapie and CWD, Canadian Food Inspection Agency, Ottawa, Ontario, Canada

P-154 **Prion infectivity detected in swine challenged with chronic wasting disease via the intracerebral or oral route**

S Jo Moore
Virus and Prion Research Unit, National Animal Disease Center, ARS, USDA, United States

P-155 **Oral Transmission of Classical BSE to Adult Cattle**

Sandor Dudas
Canadian and OIE BSE Reference Laboratory, Canadian Food Inspection Agency, National Center for Animal Disease Lethbridge, Canada

P-156 **Detection of Prion Protein Specific Camelid Nanobodies: Implications for Prion Disease Therapeutic Options**

Savannah M Rocha
Colorado State University, United States

P-157 **Earthworms can act as carriers for prion disease transmission**

Sandra Pritzkow
University of Texas Health Science Center at Houston, Germany; Mitchell Center for Alzheimer's Disease and Related Brain Disorders

P-158 **Prion Protein Gene Sequences Analysis in Twelve Sheep Breeds of Pakistan**

Mohammad Farooque Hassan
China Agricultural University, Beijing, China; SBBUVAS, Sakrand Sindh, Pakistan

P-159 **The epidemiological evolution of prion infection on bovine in Romania, in the period of 2010 - 2015**

Florica Barbuceanu
Institute for Diagnosis and Animal Health, Romania; Faculty of Veterinary Medicine Bucharest

P-160 **Rapid tests might overlook bovine spongiform encephalopathy infection in goats**

Daniela Meloni
CEA, Istituto Zooprofilattico Sperimentale dl Piemonte, Liguria e Valle d'Aosta, Turin, Italy

P-161 **A high incidence of atypical scrapie in a closed flock of Cheviot sheep**

Fiona Houston
Neurobiology Division, The Roslin Institute, University of Edinburgh, United Kingdom

P-162 **Local and Traditional Knowledge in Monitoring of Chronic Wasting Disease and Wildlife Health in Western Canada**

Brenda L Parlee
Dept. Resource Economics & Env. Sociology, Faculty of Agricultural, life and Environmental Sciences, University of Alberta, Canada

EP-010 **Simplified Rapid Detection of Prions in Biological Fluids Using Particle Extraction and Real-time Quaking Induced Conversion**

Nathaniel D Denkers
Colorado State University, Dept. Microbiology, Immunology, and Pathology, United States

EP-011 **Neuronal death and prion diseases**

Corinne I Lasmezas
Department of Immunology and Microbial Science, Department of Neuroscience, The Scripps Research Institute, United States

EP-012 **Delipidation of brain tissue partially removed the inhibitory effect of prion amyloid formation**

Yoshifumi Iwamaru
National Institute of Animal Health, Japan

EP-013 **Withdrawn**

P-163 **Active vaccination against chronic wasting disease using multimeric rec-PrP: A promising approach to contain CWD**

Dalia HA Abdelaziz
Department of Comparative Biology & Experimental Medicine, Faculty of Veterinary Medicine, University of Calgary, Alberta, Canada

P-164 **Adsorption of Soluble Prions by Metals Is Limited by Plasma**

Maurizio Pocchiari
Istituto Superiore di Sanità, Italy

P-165 **CJD incidents in Japan**

Ichiro Takumi
Department of Neurosurgery, Nippon Medical School Musashi Kosugi Hospital, Japan; Japan CJD Indecent Committee

P-166 **Inactivation of atypical and classical BSE prions by laboratory-scale autoclaving**

James Hope
Animal and Plant Health Agency, United Kingdom

P-168 **Three-dimensional cultures of murine neurones demonstrate prion-induced plaque pathology and cell death**

Cathryn L Haigh
Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Australia

P-169 **Building a Program for Community-Based Monitoring of Wildlife Health - Lessons for Surveillance of Chronic Wasting Disease in Moose and Deer in Western Canada**

Brenda L. Parlee
Dept. of Resource Economics and Environmental Sociology, Faculty of Agricultural, life and Environmental Sciences, University of Alberta, Canada

EP-020 **Prion seeding activity is widely distributed in tissues of sporadic Creutzfeldt-Jakob disease patients**

Katsuya Satoh
Department of Locomotive Rehabilitation Science, Nagasaki University Graduate School of Biomedical Sciences, Japan

EP-021 **Canine Prions: A New Form of Prion Disease**

Mourad Tayebi
University of Melbourne, Veterinary Sciences, Australia